TWI867086B - 以rvx-208及sglt2抑制劑治療及/或預防主要不良心血管事件(mace)的方法 - Google Patents

以rvx-208及sglt2抑制劑治療及/或預防主要不良心血管事件(mace)的方法 Download PDF

Info

Publication number
TWI867086B
TWI867086B TW109138504A TW109138504A TWI867086B TW I867086 B TWI867086 B TW I867086B TW 109138504 A TW109138504 A TW 109138504A TW 109138504 A TW109138504 A TW 109138504A TW I867086 B TWI867086 B TW I867086B
Authority
TW
Taiwan
Prior art keywords
mace
sglt2
patients
individual
cardiovascular
Prior art date
Application number
TW109138504A
Other languages
English (en)
Chinese (zh)
Other versions
TW202131924A (zh
Inventor
肯尼斯 尤金 勒碧歐達
克里斯多夫 洛斯 阿姆斯壯 哈里戴
亞茲 納伊 坎
Original Assignee
加拿大商瑞斯弗洛吉克斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加拿大商瑞斯弗洛吉克斯公司 filed Critical 加拿大商瑞斯弗洛吉克斯公司
Publication of TW202131924A publication Critical patent/TW202131924A/zh
Application granted granted Critical
Publication of TWI867086B publication Critical patent/TWI867086B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
TW109138504A 2019-11-05 2020-11-04 以rvx-208及sglt2抑制劑治療及/或預防主要不良心血管事件(mace)的方法 TWI867086B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962930860P 2019-11-05 2019-11-05
US62/930,860 2019-11-05

Publications (2)

Publication Number Publication Date
TW202131924A TW202131924A (zh) 2021-09-01
TWI867086B true TWI867086B (zh) 2024-12-21

Family

ID=75849803

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109138504A TWI867086B (zh) 2019-11-05 2020-11-04 以rvx-208及sglt2抑制劑治療及/或預防主要不良心血管事件(mace)的方法

Country Status (18)

Country Link
US (1) US12551484B2 (cg-RX-API-DMAC10.html)
EP (1) EP4054584B1 (cg-RX-API-DMAC10.html)
JP (1) JP7502811B2 (cg-RX-API-DMAC10.html)
KR (1) KR102935008B1 (cg-RX-API-DMAC10.html)
CN (1) CN114650824A (cg-RX-API-DMAC10.html)
AU (1) AU2020377539B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022008223A2 (cg-RX-API-DMAC10.html)
CA (1) CA3160147A1 (cg-RX-API-DMAC10.html)
DK (1) DK4054584T3 (cg-RX-API-DMAC10.html)
ES (1) ES3042146T3 (cg-RX-API-DMAC10.html)
FI (1) FI4054584T3 (cg-RX-API-DMAC10.html)
HU (1) HUE073043T2 (cg-RX-API-DMAC10.html)
IL (1) IL292696B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022005029A (cg-RX-API-DMAC10.html)
PL (1) PL4054584T3 (cg-RX-API-DMAC10.html)
PT (1) PT4054584T (cg-RX-API-DMAC10.html)
TW (1) TWI867086B (cg-RX-API-DMAC10.html)
WO (1) WO2021090061A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12551484B2 (en) 2019-11-05 2026-02-17 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
EP4236957A4 (en) * 2020-10-30 2024-08-07 Resverlogix Corp. METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR
AU2021368618B2 (en) 2020-10-30 2025-02-27 Resverlogix Corp. Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
WO2022155303A1 (en) * 2021-01-14 2022-07-21 Lexicon Pharmaceuticals, Inc. Sotagliflozin for treating or preventing cardiovascular diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016525A2 (en) 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
KR20110135411A (ko) 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
CN106075451A (zh) 2009-05-27 2016-11-09 阿斯利康(瑞典)有限公司 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
US20130281398A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
PL2986304T3 (pl) 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
BR112016003584A8 (pt) 2013-08-21 2018-01-30 Resverlogix Corp composições farmaceuticas e uso das mesmas para regressão de placa acelerada
KR20160043118A (ko) 2013-08-21 2016-04-20 리스버로직스 코퍼레이션 가속화된 경화반 퇴행을 위한 조성물 및 치료방법
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
MA43037A (fr) * 2015-10-02 2018-08-08 Dana Farber Cancer Inst Inc Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle
JP6849804B2 (ja) 2016-12-09 2021-03-31 クリスタル ファーマシューティカル(スーチョウ)カンパニー,リミテッド ブロモドメインタンパク質阻害薬の結晶形及びその製造方法並びに用途
US11419883B2 (en) 2017-05-05 2022-08-23 The Regents Of The University Of California Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes
US12551484B2 (en) 2019-11-05 2026-02-17 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
KR20220124736A (ko) 2020-01-08 2022-09-14 리스버로직스 코퍼레이션 Bet 브로모도메인 억제제 및 디펩티딜 펩티다아제 4 억제제의 조합을 이용해 주요 심혈관 이상 반응(mace)을 치료 및/또는 예방하는 방법
AU2021368618B2 (en) 2020-10-30 2025-02-27 Resverlogix Corp. Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
EP4236957A4 (en) 2020-10-30 2024-08-07 Resverlogix Corp. METHODS OF LOWERING HBA1C LEVELS USING A COMBINATION OF A BET BROMODOMAIN INHIBITOR AND A SODIUM-DEPENDENT GLUCOSE TRANSPORT-2 INHIBITOR

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Deedwania P, Acharya T. Cardiovascular Protection with Anti-hyperglycemic Agents. Am J Cardiovasc Drugs. 2019/02/15
期刊 Ghosh GC, Bhadra R, Ghosh RK, Banerjee K, Gupta A. RVX 208: A novel BET protein inhibitor, role as an inducer of apo A-I/HDL and beyond. Cardiovasc Ther. 2017/04/19

Also Published As

Publication number Publication date
CN114650824A (zh) 2022-06-21
US12551484B2 (en) 2026-02-17
EP4054584A4 (en) 2023-11-08
MX2022005029A (es) 2022-07-12
TW202131924A (zh) 2021-09-01
KR20220098757A (ko) 2022-07-12
IL292696B2 (en) 2026-05-01
CA3160147A1 (en) 2021-05-14
IL292696B1 (en) 2026-01-01
KR102935008B1 (ko) 2026-03-09
EP4054584A1 (en) 2022-09-14
JP7502811B2 (ja) 2024-06-19
IL292696A (en) 2022-07-01
US20220370452A1 (en) 2022-11-24
ES3042146T3 (en) 2025-11-18
DK4054584T3 (en) 2025-09-01
FI4054584T3 (fi) 2025-08-22
HUE073043T2 (hu) 2025-12-28
AU2020377539A1 (en) 2022-05-19
JP2023500685A (ja) 2023-01-10
BR112022008223A2 (pt) 2022-09-06
PL4054584T3 (pl) 2025-11-03
EP4054584B1 (en) 2025-07-09
PT4054584T (pt) 2025-07-16
WO2021090061A1 (en) 2021-05-14
AU2020377539B2 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
CA2851996C (en) Pharmaceutical compositions for substituted quinazolinones
KR102935008B1 (ko) Bet 브로모도메인 억제제 및 나트륨 의존 글루코스 수송 2 억제제와 병용하여 주요 부정적 심혈관 사건 (mace)을 치료 및/또는 예방하는 방법
JP2021523887A (ja) XIIa因子インヒビター
TWI882058B (zh) 以bet溴結構域抑制劑及二肽基肽酶4抑制劑之組合治療及/或預防主要不良心血管事件(mace)的方法
JP2023547475A (ja) Betブロモドメイン阻害剤及びナトリウム依存性グルコース輸送体2阻害剤の組み合わせを用いて腎機能を改善するための方法
US20230398137A1 (en) Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
HK40081394B (en) Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
HK40081394A (en) Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
EA047426B1 (ru) Способы лечения и/или предотвращения серьезных нежелательных сердечно-сосудистых явлений (снсся) с помощью комбинации ингибитора бромодомена bet и ингибитора натрий-глюкозного котранспортера 2-го типа
EA049336B1 (ru) Способы улучшения функции почек при помощи комбинации ингибитора бромодомена bet и ингибитора натрий-зависимого транспортера глюкозы 2 типа
WO2015134357A1 (en) Modulators of insulin receptor